Rittgen W - Search Results

1

Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes.

Schmezer P, Rajaee-Behbahani N, Risch A, Thiel S, Rittgen W, Drings P, Dienemann H, Kayser KW, Schulz V, Bartsch H. Schmezer P, et al. Among authors: rittgen w. Mutagenesis. 2001 Jan;16(1):25-30. doi: 10.1093/mutage/16.1.25. Mutagenesis. 2001. PMID: 11139596

2

Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer.

Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, Schulz V, Drings P, Thiel S, Bartsch H. Rajaee-Behbahani N, et al. Among authors: rittgen w. Int J Cancer. 2001 Mar 20;95(2):86-91. doi: 10.1002/1097-0215(20010320)95:2<86::aid-ijc1015>3.0.co;2-b. Int J Cancer. 2001. PMID: 11241317

3

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.

Volm M, Rittgen W, Drings P. Volm M, et al. Among authors: rittgen w. Br J Cancer. 1998 Feb;77(4):663-9. doi: 10.1038/bjc.1998.106. Br J Cancer. 1998. PMID: 9484827 Free PMC article.

4

Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR.

Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P, von Knebel Doeberitz M. Lacroix J, et al. Among authors: rittgen w. Int J Cancer. 2001 Apr 1;92(1):1-8. Int J Cancer. 2001. PMID: 11279599

5

Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors.

Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, Altevogt P, Bodenmüller W, Gassler N, Schnabel PA, Dienemann H, Marmé A, Hohenfellner M, Haferkamp A, Pfitzenmaier J, Gröne HJ, Kolb A, Büchler P, Büchler M, Friess H, Rittgen W, Edler L, Debatin KM, Krammer PH, Rutz HP, Herr I. Zhang C, et al. Among authors: rittgen w. Cancer Biol Ther. 2007 Feb;6(2):278-87. doi: 10.4161/cbt.6.2.3652. Epub 2007 Feb 27. Cancer Biol Ther. 2007. PMID: 17224649 Free article.

6

In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.

Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U; Dermatologic Cooperative Oncology Group. Ugurel S, et al. Among authors: rittgen w. Clin Cancer Res. 2006 Sep 15;12(18):5454-63. doi: 10.1158/1078-0432.CCR-05-2763. Clin Cancer Res. 2006. PMID: 17000680 Clinical Trial.

7

Fitting epidemiologic follow-up studies with cumulative damage models.

Becker N, Rittgen W. Becker N, et al. Among authors: rittgen w. Math Biosci. 1994 Apr;120(2):147-63. doi: 10.1016/0025-5564(94)90050-7. Math Biosci. 1994. PMID: 8204982

8

Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.

Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Ugurel S, et al. Among authors: rittgen w. Int J Cancer. 2005 Dec 10;117(5):825-30. doi: 10.1002/ijc.21073. Int J Cancer. 2005. PMID: 15957165

9

Statistical issues of quality control in organised breast cancer screening.

Rittgen W, Becker N. Rittgen W, et al. J Epidemiol Biostat. 2001;6(6):425-32. doi: 10.1080/135952201317225453. J Epidemiol Biostat. 2001. PMID: 11831678

10

Cellular predictive factors for the drug response of lung cancer.

Volm M, Rittgen W. Volm M, et al. Among authors: rittgen w. Anticancer Res. 2000 Sep-Oct;20(5B):3449-58. Anticancer Res. 2000. PMID: 11131647

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters